![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, December 21, 2014 12:34:44 PM
I fully expect that Brilacidin's timeline to approval will benefit substantially from the QIDP designation.
What are the expectations concerning the timeline for bringing Brilacidin to market ? If we look at Cubist and the just approved Zerbaxa which btw also got QIDP designation and priority review they published topline results late 2011. 2 pivotal phase 3s and 3 years later they got the FDA approval a couple of days ago.
Now, Cellceutix began patient enrollment for Phase IIb in February and we are now awaiting bottom-line results and a Phase III seems imminent. Obviously, Leo moves very fast but will we need one or two Phase 3s ? And how many patients will be required ? The Phase IIb enrolled 215 patients and I think a pivotal P3 will require at least 4 times that.
So isn't a PDUFA date somewhere late 2017 or Q1 2018 a fairly realistic bet for Brilacidin ABSSSI? - FarmaZutical
On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law...
...The FDA is required to establish and maintain a list of qualifying pathogens and to adopt final regulations for QIDPs by 09 Jul 2014. There will be a 60 day comment period on the proposed rules, and the rules must be published 30 days before the effective date.
http://www.ask-cato.com/2012/08/fdasia-part-3-generating-antibiotic-incentives-now-gain-and-drug-approval-and-patient-access-changes/
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM